Study

Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease? – Cost Effective Supplements

Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease?

Quick navigation


http://www.ncbi.nlm.nih.gov/pubmed/8541578


Conclusion of this study

All patients were treated with TUDCA (10-13 mg/day) for three months and the determination of PCNA (Proliferating Cell Nuclear Antigen) expression was used to assess the proliferative activity of hepatocytes at the beginning and at the end of treatment. TUDCA reduced both ALT and Knodell's score in the 5 patients in whom a significant increase of PCNA-LI (p < 0.05) was observed after treatment. TUDCA administration seems to stimulate hepatocyte proliferation in man.


Supplements analyzed in this study

TUDCA

Health conditions analyzed in this study

No health conditions information for this study.

Functions related to this study

Detox


Moderately Positive
TUDCA


Body systems related to this study


Digestive System
Scroll to top